Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 09, 2024

BUY
$32.76 - $39.56 $76,592 - $92,491
2,338 Added 4.76%
51,485 $1.8 Million
Q4 2023

Feb 08, 2024

BUY
$14.5 - $38.0 $4,669 - $12,236
322 Added 0.66%
49,147 $1.87 Million
Q3 2023

Nov 09, 2023

SELL
$15.75 - $26.31 $21,168 - $35,360
-1,344 Reduced 2.68%
48,825 $895,000
Q2 2023

Aug 08, 2023

BUY
$16.96 - $27.82 $95,162 - $156,098
5,611 Added 12.59%
50,169 $1.3 Million
Q1 2023

May 11, 2023

BUY
$18.45 - $27.14 $61,881 - $91,027
3,354 Added 8.14%
44,558 $841,000
Q4 2022

Feb 14, 2023

BUY
$20.18 - $33.33 $114,238 - $188,681
5,661 Added 15.93%
41,204 $1.02 Million
Q3 2022

Nov 10, 2022

BUY
$11.58 - $24.73 $31,254 - $66,746
2,699 Added 8.22%
35,543 $638,000
Q2 2022

Aug 11, 2022

BUY
$8.52 - $25.26 $37,786 - $112,028
4,435 Added 15.61%
32,844 $373,000
Q1 2022

May 12, 2022

BUY
$19.89 - $43.18 $65,617 - $142,450
3,299 Added 13.14%
28,409 $633,000
Q4 2021

Feb 10, 2022

BUY
$26.75 - $46.02 $18,778 - $32,306
702 Added 2.88%
25,110 $1.1 Million
Q3 2021

Nov 12, 2021

BUY
$25.18 - $37.81 $61,212 - $91,916
2,431 Added 11.06%
24,408 $813,000
Q2 2021

Aug 05, 2021

BUY
$14.69 - $27.52 $322,842 - $604,807
21,977 New
21,977 $605,000
Q1 2021

May 06, 2021

SELL
$16.27 - $41.26 $105,592 - $267,777
-6,490 Closed
0 $0
Q4 2020

Feb 10, 2021

BUY
$15.96 - $50.0 $103,580 - $324,500
6,490 New
6,490 $214,000

Others Institutions Holding INBX

# of Institutions
1
Shares Held
18.6K
Call Options Held
0
Put Options Held
0

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $570M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.